Quality of life (QoL) in patients with heart failure with preserved ejection fraction (HFpEF): a systematic review

26 August 2022 (08:00 - 19:30)

Organised by:

Sign in to view the resources

Sign in for access options

About the speaker

Doctor Jieling Chen

AstraZeneca BioPharmaceuticals, Gaithersburg (United States of America)

5 More presentations in this session

Presentation thumbnail

Impact of age on the utility of CardioMEMs device to guide heart failure therapy: analysis of the National Readmissions Database

Assistant Professor A. Briasoulis (Athens, GR)

Abstract Slides

Presentation thumbnail

Determinants and prognostic impact of afterload mismatch after MitraClip implantation

Doctor F. Angelini (Turin, IT)

Abstract Slides

Presentation thumbnail

Heart failure with mildly reduced ejection fraction: not a mid-range prognosis

Doctor J. Borges-Rosa (Coimbra, PT)

Abstract Slides

Presentation thumbnail

The prognostic value of sleep disordered breathing and the hypoxemic burden in HFpEF patients

Miss S. Mourmans (Maastricht, NL)

Abstract Slides

Presentation thumbnail

Systemic microvascular response to insulin is associated with risk of heart failure with preserved ejection fraction in women with type 2 diabetes

Doctor E. Dal Canto (Utrecht, NL)

Abstract Slides

Access the full session

Session thumbnail

Chronic heart failure - HFpEF - HFrEF - HFmREF

The Event

Event poster

ESC Congress 2022

26 August - 29 August 2022

You may be interested in

Congress Presentation

Distinguishing heart failure with reduced ejection fraction from heart failure with preserved ejection fraction: a phenomics approach.

Congress Presentation

Pharmacotherapy in HFpEF: where do cardiometabolic drugs fit in?

Congress Session

Clinical phenotypes of heart failure with preserved ejection fraction

ESC 365 is supported by

novartis

Explore sponsored resources

ESC 365 is supported by

novartis

Explore sponsored resources